GLP-1 and GIP Peptide Drugs May Protect the Heart by Directly Remodeling the Fat That Surrounds It | Research

The takeaway

GLP-1 and GIP peptide drugs may protect against heart disease not just through weight loss, but by directly remodeling epicardial fat via local receptor activation — and the resulting inflammation may actually be beneficial.

Direct receptor activation
Epicardial fat expresses both GLP-1 and GIP receptors, suggesting peptide drugs like tirzepatide interact directly with the heart's fat depot to drive cardiovascular protection

What the researchers found

This review proposes a paradigm shift in understanding epicardial adipose tissue (EAT) inflammation: rather than being purely harmful, EAT inflammation may be a necessary process for fat tissue remodeling and an adaptive response to GLP-1 and GIP peptide drug treatment. Epicardial fat expresses both GLP-1 and GIP receptors, suggesting these peptide drugs interact directly with this cardiac fat depot.

Activation of EAT GLP-1R and GIP-R may induce a beneficial balance — increasing healthy fat cell formation (adipogenesis) while reducing dangerous ectopic fat accumulation around the heart. This reframing suggests the cardiovascular benefits of liraglutide, semaglutide, and tirzepatide may be partly mediated through beneficial EAT inflammation and remodeling.

Why it matters

Epicardial fat is now recognized as a major driver of coronary artery disease and atrial fibrillation. Understanding that GLP-1/GIP peptide drugs can directly remodel this cardiac fat depot — and that the resulting inflammation is actually beneficial — fundamentally changes how we understand the cardiovascular protection these drugs provide. This suggests their heart benefits go beyond weight loss and blood sugar control to direct modification of the most dangerous fat in the body.

The numbers in context

GLP-1R and GIP-R both expressed on EAT · 3 drugs discussed (liraglutide, semaglutide, tirzepatide) · EAT linked to CAD and AF · Paradigm shift from harmful to adaptive inflammation

How the study worked

This is a narrative review and perspective article synthesizing evidence from studies on epicardial adipose tissue biology, GLP-1/GIP receptor expression in fat tissue, and clinical data on the cardiovascular effects of incretin-based peptide drugs.

Who was studied

Review article discussing mechanisms relevant to patients with obesity, type 2 diabetes, coronary artery disease, and atrial fibrillation

What this study cannot tell us

This is a conceptual review proposing a paradigm shift, not a study with new experimental data. The hypothesis that EAT inflammation from GLP-1/GIP drugs is beneficial rather than harmful requires direct testing. The mechanisms linking EAT receptor activation to cardiovascular outcomes are not fully established. Whether EAT remodeling is a major or minor contributor to the cardiovascular benefits of these drugs compared to other mechanisms (weight loss, glucose control, anti-atherosclerotic effects) is unknown.

How to read the evidence

This is a narrative review and perspective article proposing a new conceptual framework. It synthesizes existing data but does not present new experimental evidence. The paradigm shift requires prospective validation.

When this study was published

Published in 2025, this review reflects the current frontier of understanding how GLP-1/GIP peptide drugs achieve cardiovascular protection, a topic of intense ongoing research.

The bigger picture

The cardiovascular benefits of GLP-1 drugs have been one of the biggest stories in modern medicine, but the exact mechanisms remain debated. This review adds an important piece to the puzzle: direct modification of the most dangerous fat depot in the body. If confirmed, this mechanism would further distinguish GLP-1/GIP drugs from other weight-loss medications and support their use specifically for cardiovascular risk reduction, even in patients who don't lose significant weight.

Questions still open

Can imaging studies directly measure EAT remodeling in patients on GLP-1/GIP drugs to test this hypothesis?
Is the beneficial EAT inflammation response different between GLP-1 agonists and dual GIP/GLP-1 agonists like tirzepatide?
Could EAT volume or inflammation status serve as a biomarker for cardiovascular response to incretin-based therapy?

Common questions

What is epicardial fat and why is it dangerous?

Epicardial adipose tissue (EAT) is a layer of fat that sits directly on the surface of the heart, between the heart muscle and the protective sac around it. Unlike fat elsewhere in the body, EAT is in direct contact with coronary arteries and heart muscle. When it becomes inflamed, it releases harmful molecules that promote plaque buildup in coronary arteries and can trigger irregular heartbeat (atrial fibrillation).

How could inflammation from a drug be beneficial?

The review proposes that not all fat inflammation is harmful. When GLP-1/GIP drugs activate receptors on epicardial fat, the inflammation they cause may be a remodeling process — the fat tissue reorganizes to create healthy fat cells that safely store excess lipids, rather than allowing dangerous fat accumulation around heart tissue. Think of it like controlled demolition and rebuilding, versus an uncontrolled fire.

Read the original research

Epicardial Fat Inflammation and GLP-1/GIP Receptor Analogs: Are we Shifting our Perspective?

Current cardiology reports, 27(1), 161

View on PubMed ↗Publisher’s paper ↗

Citation

Iacobellis, Gianluca. (2025). Epicardial Fat Inflammation and GLP-1/GIP Receptor Analogs: Are we Shifting our Perspective?. Current cardiology reports, 27(1), 161. https://doi.org/10.1007/s11886-025-02325-5